Immunic (NASDAQ:IMUX) Receives Buy Rating from B. Riley

Immunic (NASDAQ:IMUX - Get Free Report)'s stock had its "buy" rating restated by research analysts at B. Riley in a note issued to investors on Friday,Benzinga reports. They presently have a $5.00 price objective on the stock, down from their prior price objective of $6.00. B. Riley's price target indicates a potential upside of 444.66% from the company's current price.

Several other equities analysts have also weighed in on the company. D. Boral Capital reaffirmed a "buy" rating and issued a $17.00 price objective on shares of Immunic in a research note on Wednesday, April 30th. Wall Street Zen downgraded shares of Immunic from a "hold" rating to a "sell" rating in a report on Thursday, March 20th. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price objective on shares of Immunic in a report on Thursday, May 1st. Finally, William Blair reissued an "outperform" rating on shares of Immunic in a research note on Friday, May 16th. One equities research analyst has rated the stock with a sell rating, six have given a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $13.00.

Immunic Price Performance

Shares of IMUX opened at $0.92 on Friday. The firm has a market cap of $87.96 million, a P/E ratio of -0.74 and a beta of 1.73. The company has a 50 day simple moving average of $1.04 and a two-hundred day simple moving average of $1.08. Immunic has a 1 year low of $0.83 and a 1 year high of $2.11.

Immunic (NASDAQ:IMUX - Get Free Report) last released its earnings results on Thursday, May 15th. The company reported ($0.25) earnings per share for the quarter, meeting the consensus estimate of ($0.25). On average, sell-side analysts anticipate that Immunic will post -0.94 earnings per share for the current year.

Institutional Investors Weigh In On Immunic

Hedge funds have recently added to or reduced their stakes in the stock. Invesco Ltd. bought a new position in shares of Immunic during the 4th quarter worth approximately $37,000. HB Wealth Management LLC acquired a new stake in Immunic in the 4th quarter valued at $81,000. Barclays PLC bought a new stake in Immunic during the 4th quarter worth about $84,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Immunic by 90.0% during the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 204,579 shares of the company's stock worth $205,000 after buying an additional 96,894 shares during the last quarter. Finally, Bridgeway Capital Management LLC grew its holdings in shares of Immunic by 11.5% in the 4th quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company's stock valued at $215,000 after acquiring an additional 22,200 shares in the last quarter. Institutional investors own 51.82% of the company's stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.